Contineum Therapeutics Inc
NASDAQ:CTNM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Contineum Therapeutics Inc
Net Change in Cash
Contineum Therapeutics Inc
Net Change in Cash Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Change in Cash | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Contineum Therapeutics Inc
NASDAQ:CTNM
|
Net Change in Cash
$53.7m
|
CAGR 3-Years
285%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Baker Hughes Co
NASDAQ:BKR
|
Net Change in Cash
$1.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
3%
|
CAGR 10-Years
11%
|
|
|
Schlumberger NV
NYSE:SLB
|
Net Change in Cash
-$508m
|
CAGR 3-Years
-72%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-29%
|
|
|
Halliburton Co
NYSE:HAL
|
Net Change in Cash
$199m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-30%
|
|
|
Symbotic Inc
NASDAQ:SYM
|
Net Change in Cash
$516.8m
|
CAGR 3-Years
38%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
R
|
Reddit Inc
NYSE:RDDT
|
Net Change in Cash
$391.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
|
Contineum Therapeutics Inc
Glance View
Contineum Therapeutics Inc is a US-based company operating in industry. The company is headquartered in San Diego, California and currently employs 31 full-time employees. The company went IPO on 2024-04-05. Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation, and immunology (NI&I) indications with high unmet need. Its pipeline includes PIPE-791, CTX-343, and PIPE-307. Its lead asset, PIPE-791, is novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) in development for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (Progressive MS). The firm is developing CTX-343, a peripherally restricted LPA1R antagonist to further expand clinical indications involving LPA1R antagonism. Its second drug candidate, PIPE-307, is a novel, small molecule, selective inhibitor of M1R, which is in clinical development for the potential treatment of depression and relapse remitting MS (RRMS).
See Also
What is Contineum Therapeutics Inc's Net Change in Cash?
Net Change in Cash
53.7m
USD
Based on the financial report for Dec 31, 2025, Contineum Therapeutics Inc's Net Change in Cash amounts to 53.7m USD.
What is Contineum Therapeutics Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 3Y
285%
Over the last year, the Net Change in Cash growth was 736%. The average annual Net Change in Cash growth rates for Contineum Therapeutics Inc have been 285% over the past three years .
